Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(BMS-387032; SNS 032; SNS032; BMS 387032; BMS387032)
SNS-032 Chemical Structure
|Product name: SNS-032|
|Cat. No.: HY-10008|
SNS-032(BMS-387032) is a potent inhibitor of cyclin-dependent kinases (cdks) 9, 2 and 7 (IC50 values are 4, 38 and 62 nM respectively).
IC50 Value: 38 nM(for CDK2); 62 nM(for CDK7); 4 nM(for CDK9)
in vitro: BMS-387032 displays no activity against 190 additional kinases (IC50 >1000 nM). BMS-387032 arrests the cell cycle at G2/M; inhibits transcription, proliferation and colony formation, and induces apoptosis in RPMI-8226 multiple myeloma cells. BMS-387032 prevents tumor cell-induced VEGF secretion and in vitro angiogenesis. SNS-032 inhibits three dimensional capillary network formations of endothelial cells. SNS-032 completely prevents U87MG cell–mediated capillary formation of HUVECs. In addition, SNS-032 significantly prevents the production of VEGF in both cell lines, SNS-032 prevents in vitro angiogenesis, and this action is attributable to blocking of VEGF. Preclinical studies have shown that SNS-032 induces cell cycle arrest and apoptosis across multiple cell lines.
in vivo: SNS-032 prevents tumor cell-induced VEGF secretion in a tumor coculture model. SNS-032, a new CDK inhibitor, is more selective and less cytotoxic and has been shown to prolong stable disease in solid tumors.
|M.Wt||380.53||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||2.6279 mL||13.1396 mL||26.2791 mL|
|5 mM||0.5256 mL||2.6279 mL||5.2558 mL|
|10 mM||0.2628 mL||1.3140 mL||2.6279 mL|
. Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM.A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.Invest New Drugs. 2008 Feb;26(1):59-65. Epub 2007 Oct 16.
. Wu Y, Chen C, Sun X, Shi X, Jin B, Ding K, Yeung SC, Pan J.Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.Clin Cancer Res. 2012 Apr 1;18(7):1966-78. Epub 2012 Mar 23.
. Walsby E, Lazenby M, Pepper C, Burnett AK.The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.Leukemia. 2011 Mar;25(3):411-9. Epub 2011 Jan 7.
1NM-PP1(PP1 Analog II) is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors(IC50=28 uM vSrc; 4.2 nM v-Src-as1 I338G).
AMG 925 is a potent and selective dual inhibtor of CDK4/FLT3 with IC50s of 1.5 nM and 2.4 nM for CDK4 and FLT3, respectively; with IC50 of 19 nM in MOLM-13 cell.
AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM. It is less potent to CDK5/6.
6-BIO(6-Bromoindirubin-3(acute)-oxime) is a potent and selective inhibitor of GSK-3 and CDK1–cyclinB complex with IC50 of 5 nM /320 nM/83 nM for GSK-3(alpha)(beta)/CDK1/CDK5 respectively.
BMS-265246 is a potent and selective CDK1/2 inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively.
Briciclib is a small molecule that suppresses cyclin D1 accumulation in cancer cells.
Ca2(addition) channel agonist 1 is a N-type Ca2(addition) channel activity agonist, with EC50 of 14.23 uM, also inhibits cdk2 kinase activity with EC50 of 3.34 uM.
CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of <8 nM.
CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection.
CDK9-IN-2 is a novel cyclin-dependent kinase 9(CDK9) inhibitor.
Other Countries & RegionsSee Worldwide Distributors